Page 22 - Celcuity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) - Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor - MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, presented results of studies evaluating gedatolisib (a pan-PI3K/mTOR inhibitor), ina...

Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update Preliminary Phase 1b Data - Gedatolisib showed a potentially differentiated safety and tolerability profile - Corporate Update - Proceeds from first $15 million tranche increase cash-on-hand to $44 million - - Drug development capabilities and team broadened and expanded - - Conference call and webcast scheduled for today, April 8 at 5 p...

Search jobs 08-Apr-2021 Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer -Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted - Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy - Management to host conference call/webcast today, April 8, 2021, at 5:00 p.m. ET MINNEAPOLIS...

4/9/2021 7:43:32 PM GMT | By Benzinga Team Toward the end of trading Friday, the Dow traded up 0.42% to 33,645.90 while the NASDAQ rose 0.06% to 13,837.33. The S&P also rose, gaining 0.32% to 4,110.11. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 31,003,070 cases with around 560,110 deaths. Brazil reported over 13,279,850 COVID-19 cases with 345,020 deaths, while India confirmed a total of at least 13,060,540 cases and 167,640 deaths. In total, there were at least 134,038,180 cases of COVID-19 worldw...

BRIEF-Celcuity Reports Preliminary Efficacy & Safety Analysis For Gedatolisib Showed 53 Of 88 Evaluable Patients Had An Objective Response Reuters 2 days ago April 8 (Reuters) - Celcuity Inc: * CELCUITY REPORTS PRELIMINARY DATA FROM PHASE 1B TRIAL OF GEDATOLISIB PLUS IBRANCE® AND ENDOCRINE THERAPY FOR PATIENTS WITH ER+/HER2- METASTATIC BREAST CANCER AND PROVIDES CORPORATE UPDATE * CELCUITY INC - PRELIMINARY EFFICACY & SAFETY ANALYSIS FOR GEDATOLISIB SHOWED 53 OF 88 EVALUABLE PATIENTS (60%) HAD AN OBJECTIVE RESPONSE * CELCUITY INC - PRELIMINARY EFFICACY & SAFETY ANALYSIS FOR GEDATOLISIB SHO...